Aurinia Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of immunosuppressive therapeutics.
Aurinia Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Aurinia Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Aurinia Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Aurinia Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Aurinia Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Aurinia Pharmaceuticals assets
Aurinia Pharmaceuticals cash flows

Aurinia Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
AUPH:USAurinia PharmaceuticalsCommon share-CA05156V1022$6.76
Aurinia Pharmaceuticals news
10.05.2022
Aurinia Pharmaceuticals' IFRS loss for 3 months of 2022 was $37.63 million, down 25.3% from $50.379 million in the previous year. Revenue increased 23.7 times to $21.625 million compared to $0.914 million a year earlier.
Source: ir.auriniapharma.com pictogram ir.auriniapharma.com
Pictogram next
28.02.2022
Aurinia Pharmaceuticals' IFRS loss for 2021 was $180.966 million, up 76.2% from $102.68 million in the previous year. Revenue decreased 9% to $45.605 million compared to $50.118 million a year earlier.
Source: ir.auriniapharma.com pictogram ir.auriniapharma.com
Pictogram next
03.11.2021
Aurinia Pharmaceuticals' IFRS loss for 9M 2021 was $147.644 million, up 56.1% from $94.606 million in the previous year. Revenue increased multiple times to $22.201 million from $0.088 million a year earlier.
Source: ir.auriniapharma.com pictogram ir.auriniapharma.com
Pictogram next
06.08.2021
Aurinia Pharmaceuticals reported an IFRS loss of $97.389 million for 6 months 2021, up 85.6% from $52.476 million in the previous year. Revenue increased multiple times to $7.534 million compared to $0.059 million a year earlier.
Source: ir.auriniapharma.com pictogram ir.auriniapharma.com
Pictogram next
All Aurinia Pharmaceuticals news
General information
Company nameAurinia Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address#1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Mailing address#1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Websitewww.auriniapharma.com
Information disclosurewww.sec.gov